In our March Editorial, we argued against a proposal to add analogue insulins to the WHO Model List of Essential Medicines. Similar to five of six other public comments on the proposal submitted to WHO, we highlighted the fact that there is little evidence to support the cost-effectiveness of analogues. Encouragingly, WHO opted not to add analogues to the Model List. Cost-effective treatment is important for any prevalent chronic disease in any country, but the issue is increasingly important for care of diabetes in low-income and middle-income countries (LMICs), where resources are particularly scarce in the face of rapidly increasing need.

中文翻译：

---

为改善低收入人群的糖尿病护理开辟道路

在3月的社论中，我们反对将类似胰岛素添加到WHO WHO基本药物标准清单中的提议。与提交给世卫组织的提案有关的其他六个公共评论中的五个相似，我们强调了这样一个事实，即几乎没有证据支持类似物的成本效益。令人鼓舞的是，世卫组织选择不将类似物添加到标准清单中。具有成本效益的治疗对任何国家中任何流行的慢性病都很重要，但对于低收入和中等收入国家（LMIC）的糖尿病而言，这一问题就变得越来越重要，在这些国家中，面对快速增长的需求，资源尤其匮乏。